Epilepsy in Rare Neurological Disorders
Epygenix Therapeutics Inc. focuses on clinical research in epileptic encephalopathies, with activity centered on Dravet syndrome and Lennox-Gastaut syndrome. These conditions reflect a therapeutic interest in severe, treatment-resistant seizure disorders affecting children and adults.
- Dravet syndrome
- Lennox-Gastaut syndrome
- Seizure control
- Rare pediatric neurology
The sponsor’s clinical program is aligned with neurological disease management in populations with complex and persistent seizure burden.
Antiseizure Therapeutics
Research activity includes evaluation of clemizole hydrochloride and EPX-100 in the context of adjunctive treatment for refractory epilepsy syndromes. The therapeutic focus is on agents intended to support seizure reduction in patients with limited treatment options.
- Adjunctive therapy
- Refractory seizures
- Antiseizure agents
- Therapeutic response in epilepsy
This area reflects interest in novel pharmacologic approaches for difficult-to-manage seizure disorders.
Child and Adult Neurology
The sponsor’s studies include both children and adult participants, indicating a cross-age clinical focus within severe epilepsy care. This supports investigation of treatments across different stages of life in syndromes that often begin early and persist long term.
- Pediatric neurology
- Adult epilepsy care
- Long-term seizure disorders
- Developmental epileptic encephalopathy
The clinical scope includes age-diverse patient populations affected by chronic neurological impairment linked to epilepsy.
Multicenter Rare Disease Research
Clinical operations extend across multiple research sites and countries, supporting studies in rare disease neurology with broad participant access. The sponsor’s work is concentrated on specialized epilepsy programs requiring coordinated clinical evaluation.
- Multicenter clinical research
- Rare disease trials
- International site networks
- Specialty epilepsy centers
This footprint is consistent with research in orphan neurological conditions where trial participation depends on distributed specialist sites.
